Generics
Trajectories of prices in generic drug markets
In a study by Trujillo AJ et al., the authors adopt a group-based trajectory modelling approach to analyse the price trends of generic drugs. The analysis is conducted using price data collected quarterly over the past decade from the IBM MarketScan claims database. The study focus is to understand the trajectory patterns of these drugs and identify factors that may have influenced their pricing over time [1].
Evaluation of pharmaceutical equivalency of manufactured generic drugs in UAE
Generic medicines are pharmaceutical products manufactured to be equivalent to the brand or innovator drug products. They represent the majority of worldwide prescribed medicines; therefore, their quality is critical to ensure equivalent therapeutic outcomes
New insights into the amount of R & D for new uses of generic drugs
Generic drugs are considered indispensable to healthcare systems because they are substantially cheaper than original versions of the drugs. These drugs have become common place, within healthcare delivery, because of the anticipated financial benefits [1].
FDA releases one-year progress report for the Generic Drug Cluster
The US Food and Drug Administration’s (FDA) one-year progress report for the Generic Drug Cluster – a multi-country forum on generic drugs – explains the purpose of the Cluster and key achievements made so far.
US generics launch and approval for Dr Reddy’s and Lupin
On 7 September 2022, Dr Reddy’s Laboratories (Dr Reddy’s) announced the US launch of their generic lenalidomide capsules. And in July 2022, Lupin announced that its generic azilsartan medoxomil tablets had been approved by the US Food and Drug Administration (FDA).
Pricing and reimbursement of medicines in Canada
Canada is a wealthy country with gross domestic product (GDP) per capita of US$43,258 in 2020. It ranks 16th in the United Nations’ Human Development Index and is one of the most multicultural countries in the world. Canada’s population of more than 38 million includes a significant indigenous population. Its huge land mass means it is very sparsely populated outside urban areas. Authors from Canada and Brazil discuss the pharmaceutical pricing and reimbursement policies in Canada [1].
Medicines pricing conditions in Italy and Brazil: comparison of regulations
In the context of the National Health Services (NHS), the gearing that moves the health services comprises a legal framework, permeated by technical and economic parameters.
Pharmaceutical manufacturing companies in Brazil
Brazil is a country active in life sciences research, publications, manufacturing and exports. Biosimilars have the highest growth potential for the pharmaceutical sector in Latin America [1].
Pharmaceutical companies in Argentina
Argentina has an important pharmaceutical sector, being the third largest market in Latin America after Brazil and Mexico. Pharmaceutical companies from Denmark, France, Germany, Switzerland, the UK and the US are stablished in Argentina. Argentine market has extensive experience in the incorporation of foreign investments for the sector as well as offers multiple business opportunities.
Relevance of NTI to the treatment of epilepsy
In a mini review, author a Roy G Beran discusses what is the relevance of a narrow therapeutic index (NTI) to the treatment of epilepsy [1].
